Thanks for sending your question to Reportlinker. Here is the information you asked for:
This report published by Visiongain in March 2015, includes information on the main biosimilar drugs manufacturers and forecasts their revenues. It features outlooks from the year 2015 to 2025, results, trends and also opportunities for the industry.
Visiongain’s study looks at the top 25 key players in the biosimilar drug market, including developers, producers and marketers from big pharma and elsewhere. It assesses the potential of both established and emerging firms by analyzing products, sales, results, R&D and market share. The report contains a qualitative analysis, discussion, 61 tables, 43 charts and 2 interviews. It illustrates where the most lucrative gaps in the market occur and also explores future potential, such as recombinant therapeutic proteins. Some of the companies covered in the report include Sandoz, Teva Pharmaceutical Industries, Hospira, Celltrion, LG Life Sciences, Biocon, Mylan, Dr. Reddy’s Laboratories, Eli Lilly, Merck & Co., Bristol-Myers Squibb, Amgen, Pfizer, Merck KGaA and Boehringer In..
The study shows the market’s advances, results and potentials, covering eight biosimilar classes. These include erythropoietins, insulin, granulocyte-colony stimulating factor, somatropins, interferons, monoclonal antibodies, follicle stimulating hormones and other follow-on protein therapies. It has a revenue forecast to the year 2025 for these biosimilar medicines and also the possibilities and potentials for the involved firms.
The report also looks into the biosimilar competition for 5 therapeutic agents; Adalimumab, Infliximab, Etanercept, Darbepoetin alpha and Rituximab. It looks into original products such as Humira, Remicade, Enbrel, Aranesp and Rituxan as well as how other relevant activities that are affecting healthcare treatments,
There are many opportunities for biosimilars and this study predicts a rapid market expansion between 2015 and 2025. This research can benefit you by providing a detailed analysis of the industry to guide business decisions on protein-based medicines.
I hope you find this useful, and can see that there is a lot of useful information available through the portal about the pharmaceutical industry. If you have any additional needs or questions about our reports, please feel free to contact us.